ArticleTranslational psychiatry2026
Sex and dose-dependent effects of cannabidiol on cocaine consumption in mice.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cocaine use disorder (CUD) is a neuropsychiatric disorder marked by compulsive drug-seeking and loss of control over cocaine intake, with women experiencing a faster addictive development and greater adverse outcomes despite lower incidence compared to men. Currently, there are no effective pharmacological treatments for CUD. Cannabidiol (CBD), a multitarget compound acting mainly on mediators of the expanded endocannabinoid system, has emerged as a potential therapeutic agent for substance use disorders. Though its effects have been researched in preclinical studies with males, its role in females remains underexplored. Here, we investigated the effect of CBD on distinct phases of cocaine-seeking and taking behaviour using the intravenous self-administration (SA) paradigm in female mice. First, CBD's pharmacological profile was evaluated on anxiety-like and cognitive-task models. Consequently, animals received CBD at 10 or 20 mg/kg to assess its effects on the acquisition of cocaine-consummatory behaviours and compulsive drug-seeking following association to negative consequences like an electric foot-shock. Our findings reveal that CBD modulates cocaine-seeking behaviour in a dose-dependent manner: 10 mg/kg CBD attenuated the acquisition of SA by alteration of reward- and cognitive-related markers within the mesocorticolimbic pathway. Conversely, 20 mg/kg increased cocaine consumption post-punishment but reduced cocaine-seeking upon re-exposure to punishment-associated cues and induced an upregulation of Htr1a expression in the medial prefrontal cortex. Parallel studies in males found no effects after punishment. These results highlight the complex, dose-dependent effects of CBD on cocaine consumption patterns and underscore its potential as a modulator of specific neurobehavioral processes in CUD in female mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.